The Scottish Medicines Consortium (SMC) has accepted the use of Revlimid (lenalidomide) as a treatment for newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplantation, and who are intolerant or contraindicated to thalidomide. The approval is based on results from the FIRST (MM-020) trial which showed that Revlimid in combination with dexamethasone significantly improve progression-free survival compared to melphalan, prednisolone and thalidomide.


Read full article